IGF-1 DES
Des(1-3) IGF-1 is a truncated form of insulin-like growth factor-1 missing the first three amino acids, resulting in dramatically reduced IGFBP binding, approximately 10-fold greater potency than native IGF-1, and preferential concentration in brain tissue.
Des(1-3) IGF-1 is a naturally occurring truncated variant of insulin-like growth factor-1 that lacks the N-terminal tripeptide Gly-Pro-Glu (GPE). This three-amino-acid deletion dramatically reduces binding to insulin-like growth factor binding proteins (IGFBPs), resulting in approximately 10-fold greater biological potency compared to full-length IGF-1.
Overview
Des(1-3) IGF-1 was first isolated from bovine colostrum and subsequently identified in human brain tissue, where it constitutes the major IGF-1 variant. The removal of the Gly-Pro-Glu tripeptide from the N-terminus eliminates a critical binding site for IGFBPs, particularly IGFBP-1, -2, and -3. Since over 95% of circulating full-length IGF-1 is sequestered by IGFBPs, the reduced binding of des(1-3) IGF-1 results in dramatically more free, biologically active peptide. This makes des(1-3) IGF-1 substantially more potent than native IGF-1 on a molar basis in cell culture and in vivo models.
Mechanism of Action
IGF-1 DES (Des(1-3) IGF-1) is a naturally occurring splice variant of IGF-1 that lacks the first three N-terminal amino acids (glycine-proline-glutamate). This seemingly minor structural modification has profound pharmacological consequences because the N-terminal tripeptide is critical for binding to IGF-binding proteins (IGFBPs). With this region deleted, IGF-1 DES exhibits up to 100-fold reduced affinity for IGFBPs (particularly IGFBP-3 and IGFBP-5), meaning it circulates and acts locally in a predominantly free, unbound state rather than being sequestered in the IGFBP-3/ALS ternary complex that normally regulates native IGF-1 bioavailability.
Despite the N-terminal truncation, IGF-1 DES retains full binding affinity for the IGF-1 receptor (IGF-1R), as the receptor-binding domain resides in the central and C-terminal regions of the peptide. The dramatically increased free fraction means that at equivalent total concentrations, IGF-1 DES produces substantially greater IGF-1R occupancy and activation than native IGF-1. This translates to amplified downstream signaling through both the PI3K/Akt/mTOR pathway (driving enhanced protein synthesis, ribosomal biogenesis, and anti-apoptotic signaling) and the Ras/MAPK/ERK pathway (promoting cell proliferation and differentiation). The mTOR-mediated effects on p70S6K and 4E-BP1 phosphorylation are particularly potent, making IGF-1 DES a substantially more effective stimulator of muscle protein synthesis and hypertrophy.
The enhanced potency of IGF-1 DES makes it approximately 10 times more mitogenic than native IGF-1 in cell culture studies. When administered locally (e.g., intramuscularly), it acts with rapid onset due to its free bioavailability, strongly activating satellite cell proliferation and differentiation -- the muscle stem cells responsible for repair and growth. This potent local action, combined with its short half-life (due to lack of IGFBP-mediated protection from proteolytic degradation), makes IGF-1 DES particularly suited for targeted tissue growth effects at the site of administration rather than systemic anabolic signaling.
Reconstitution Calculator
IGF-1 DES
Des(1-3) IGF-1 is a naturally occurring truncated variant of insulin-like growth
Set up a clean workspace with all supplies ready.
7x / week for weeks
Research
Muscle Hypertrophy and Cell Proliferation
In skeletal muscle cell culture, des(1-3) IGF-1 potently stimulates myoblast proliferation and differentiation through IGF-1R activation. The enhanced free fraction compared to native IGF-1 translates to greater stimulation of protein synthesis and satellite cell activation at equivalent molar concentrations. Research in animal models demonstrates increased muscle mass and fiber hypertrophy with des(1-3) IGF-1 administration, consistent with its role as a more bioavailable form of IGF-1 (Tomas et al., 1993).
Enhanced Potency Over Native IGF-1
Ballard et al. demonstrated that des(1-3) IGF-1 is approximately 10 times more potent than full-length IGF-1 in stimulating DNA synthesis and protein accumulation in cell culture systems. This potency difference is entirely attributable to reduced IGFBP binding rather than enhanced receptor affinity, as des(1-3) IGF-1 and native IGF-1 show equivalent binding to IGF-1R in purified receptor assays (Ballard et al., 1996). The practical implication is that des(1-3) IGF-1 achieves the same biological effect at approximately one-tenth the dose.
The GPE Tripeptide
The N-terminal tripeptide Gly-Pro-Glu (GPE) that is cleaved to produce des(1-3) IGF-1 has independent biological activity. GPE itself has demonstrated neuroprotective properties, and its synthetic analog NNZ-2566 (trofinetide) has been evaluated in clinical trials for Rett syndrome and traumatic brain injury. This means the processing of full-length IGF-1 to des(1-3) IGF-1 generates two biologically active molecules with distinct but complementary neuroprotective functions.
Cell Culture Applications
Des(1-3) IGF-1 is widely used as a growth factor supplement in serum-free cell culture media due to its superior potency over native IGF-1. The reduced IGFBP interference makes it more effective and predictable in culture systems where serum-derived IGFBPs would otherwise buffer IGF-1 activity. It is routinely used in stem cell expansion, hybridoma culture, and tissue engineering research.
Brain-Specific Effects and Neuroprotection
Des(1-3) IGF-1 is the predominant form of IGF-1 in brain tissue, where it is generated by tissue-specific proteolytic processing. Its blood-brain barrier permeability and reduced IGFBP binding allow it to achieve higher effective concentrations in neural tissue than full-length IGF-1. Research demonstrates that des(1-3) IGF-1 promotes neuronal survival, stimulates neurite outgrowth, and protects against excitotoxic injury. In models of hypoxic-ischemic brain injury, des(1-3) IGF-1 administration reduced neuronal loss and improved functional outcomes (Guan et al., 1996). The neuroprotective mechanism involves activation of PI3K/Akt-mediated anti-apoptotic signaling in neurons and glial cells.
Safety Profile
Des(1-3) IGF-1 shares the general safety considerations of IGF-1 pathway activators. Its enhanced potency relative to native IGF-1 means that the same concerns apply at lower doses: hypoglycemia from insulin receptor cross-reactivity, potential promotion of pre-existing malignancies through IGF-1R-mediated cell proliferation and anti-apoptotic signaling, and effects on growth plate cartilage in developing organisms. The reduced IGFBP buffering that enhances potency also reduces the physiological "safety brake" that normally modulates IGF-1 activity. No formal clinical safety studies of des(1-3) IGF-1 have been conducted; safety data is extrapolated from native IGF-1 (mecasermin) clinical experience.
Clinical Research Protocols
Des(1-3) IGF-1 has not been evaluated in formal human clinical trials. Research protocols have been conducted in animal models and cell culture systems. Key preclinical protocols include:
- Neonatal hypoxia-ischemia (rat models): Des(1-3) IGF-1 administered intracerebroventricularly (1-50 mcg) within 2 hours of hypoxic-ischemic insult, with neuronal survival assessed at 3-7 days via histology and TUNEL staining (Guan et al., 1996)
- Cell proliferation assays: Des(1-3) IGF-1 at 10-100 ng/mL in serum-free media, measuring DNA synthesis via BrdU incorporation and protein accumulation over 24-72 hours (Ballard et al., 1996)
- Muscle anabolism (rat models): Systemic administration via osmotic minipump in dexamethasone-treated rats, measuring body composition and nitrogen balance (Tomas et al., 1993)
Pharmacokinetic Profile
- Half-life
- Longer than native IGF-1 due to reduced IGFBP binding
- Protein Binding
- Reduced to 1-10% of native IGF-1 affinity due to loss of the N-terminal tripeptide binding domain
- BBB Penetration
- Permeable; concentrated in brain tissue where it is the predominant IGF-1 form
Quick Start
- Route
- Subcutaneous injection
Research Protocols
intracerebroventricular Injection
Administered via intracerebroventricular.
| Goal | Dose | Frequency | Duration |
|---|---|---|---|
| Neonatal hypoxia-ischemia (rat models) | 1-50 mcg | Per protocol | 3-7 days(Route: Intracerebroventricular) |
subcutaneous Injection
Administered via subcutaneous injection.
Interactions
Peptide Interactions
This means the processing of full-length IGF-1 to des(1-3) IGF-1 generates two biologically active molecules with distinct but complementary neuroprotective functions.
Safety Profile
Common Side Effects
- Hypoglycemia:: Users report potential drops in blood sugar levels, necessitating a post-administration carbohydrate source.
- Local Inflammation:: Temporary redness or swelling at the site of injection is common.
- Organ Growth:: Concerns regarding potential growth of unintended tissues (like the gut) if used excessively long-term.
- Cancer Risk:: High IGF-1 levels are theoretically linked to accelerated growth of pre-existing malignant cells.
Quality Indicators
What to look for
- Human clinical trials conducted
- Naturally occurring compound
- Multiple peer-reviewed studies available
Frequently Asked Questions
References (8)
- [6]
- [9]Carlsson-Skwirut et al *Biochim Biophys Acta* Biochim Biophys Acta (1989)
- [8]
- [4]Ballard et al *Int J Biochem Cell Biol* Int J Biochem Cell Biol (1996)
- [5]Guan et al *J Cereb Blood Flow Metab* J Cereb Blood Flow Metab (1996)
- [1]Des(1-3)IGF-I: a truncated form of insulin-like growth factor-I
→ This variant is 10-fold more potent than standard IGF-1 due to reduced binding with inhibitory proteins, showing significant anabolic effects in vivo.
- [2]Secretion of insulin-like growth factor II (IGF-II) and IGF-binding protein-2 by intestinal epithelial (IEC-6) cells
→ Research demonstrates that IGF-1 variants are significantly more potent than insulin or IGF-II in stimulating protein synthesis and DNA replication in epithelial cells.
- [3]Effects of IGF-1 on the Cardiovascular System
→ IGF-1 acts as a powerful anabolic hormone that regulates cell survival, metabolic homeostasis, and vascular relaxation through nitric oxide pathways.
Humanin
Humanin is a 24-amino acid mitochondria-derived micro-peptide that protects cells from oxidative stress, inflammation, and apoptosis, with research applications in neurodegeneration, cardiovascular disease, metabolic regulation, and aging.
IGF-1 LR3
IGF-1 LR3 is a synthetic modified construct of insulin-like growth factor-1 with an extended half-life that enhances cell division, fat metabolism, and muscle repair through reduced binding to IGF binding proteins.